HOUSTON, May 16, 2025 – 10:53 AM
Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company focused on immunomodulatory therapies, will headline the third annual BioConnect Conference hosted by H.C. Wainwright this Tuesday in New York City. The event marks a pivotal opportunity for the company to connect with stakeholders as it advances its innovative pipeline targeting neurodegenerative diseases characterized by chronic inflammation and immune dysregulation.
CEO Dr. Arun Swaminathan will join executives from top-tier biotechs in a fireside chat, shedding light on Coya’s strategy to capitalize on its proprietary Treg-enhancing platforms. Management will also engage in one-on-one meetings with investors, underscoring its commitment to transparency and collaboration in transitioning from clinical research to real-world impact.
Beyond the conference, stakeholders can access a live stream of the discussion on Coya’s investor relations page at https://coyatherapeutics.com, with a 90-day replay window to assess key disclosures.
About Coya Therapeutics, Inc.
Based in Houston, Texas, Coya Therapeutics sits at the forefront of Treg biology—a field gaining traction as scientists uncover the cells’ role in tempering hyperinflammation and oxidative stress, underlying contributors to conditions like ALS, Alzheimer’s, and Parkinson’s. With Treg dysfunction prevalent across autoimmune, metabolic, and neurodegenerative disorders, the company’s platforms aim to restore immune equilibrium through innovative modalities: biologics, exosomes, and autologous cell therapies.
The crown jewel, COYA 302, merges two established compounds—low-dose interleukin-2 (LD IL-2, COYA 301) and CTLA4-Ig—into a novel subcutaneous therapy. By simultaneously boosting Treg counts and suppressing microglial activation, the dual-pathway approach positions itself as a differentiated treatment for neuroinflammatory diseases where monotherapies have faltered. “This isn’t just a drug; it’s a platform for next-generation immunotherapy,” says Coya’s leadership.
Risks and Forward-Looking Considerations
Investors should note that forward-looking statements in this release entail risks tied to clinical trial timelines, regulatory hurdles, and competitive pressures. Additionally, uncertainties around data normalization for marketing applications, manufacturing dependencies, and the ever-evolving biotech landscape temper projections of market adoption. Trade tensions, funding gaps, and unforeseen challenges in talent retention also loom—hallmarks of an industry where “feasibility” meets “capital intensity.”
Readers are advised to review Coya’s latest SEC filings for a comprehensive risk discussion. The company disclaims any intent to update these statements post-publication.
Key Contacts
Investor Contact
David Snyder, CFO
[email protected]
CORE IR
Bret Shapiro
[email protected]
(561) 479-8566
Media Contact
Kati Waldenburg
[email protected]
(212) 655-0924
View source version on businesswire.com
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/133.html
